Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
2.98
Dollar change
+0.27
Percentage change
9.96
%
Index- P/E- EPS (ttm)-24.58 Insider Own3.22% Shs Outstand1.49M Perf Week-1.32%
Market Cap4.44M Forward P/E- EPS next Y-12.35 Insider Trans0.00% Shs Float1.44M Perf Month-28.54%
Income-31.70M PEG- EPS next Q-3.80 Inst Own8.49% Short Float5.57% Perf Quarter-65.75%
Sales0.00M P/S- EPS this Y-5.50% Inst Trans32.00% Short Ratio0.99 Perf Half Y-80.05%
Book/sh8.28 P/B0.36 EPS next Y41.47% ROA-136.07% Short Interest0.08M Perf Year-91.99%
Cash/sh7.86 P/C0.38 EPS next 5Y- ROE-159.31% 52W Range2.50 - 46.00 Perf YTD-67.61%
Dividend Est.- P/FCF- EPS past 5Y11.24% ROI-257.59% 52W High-93.52% Beta-0.61
Dividend TTM- Quick Ratio2.96 Sales past 5Y0.00% Gross Margin- 52W Low19.20% ATR (14)0.48
Dividend Ex-Date- Current Ratio2.96 EPS Y/Y TTM-29.94% Oper. Margin0.00% RSI (14)32.40 Volatility10.99% 11.70%
Employees- Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.67 Target Price165.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q-5.74% Payout- Rel Volume0.37 Prev Close2.71
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume80.95K Price2.98
SMA20-21.87% SMA50-44.79% SMA200-80.53% Trades Volume29,885 Change9.96%
Date Action Analyst Rating Change Price Target Change
Jan-26-21Initiated National Securities Buy $7
Apr-29-19Initiated Noble Capital Markets Outperform $5
Mar-22-24 04:10PM
Mar-19-24 01:24PM
Mar-12-24 09:01AM
Mar-06-24 08:30AM
Feb-07-24 08:15AM
07:30AM Loading…
Feb-06-24 07:30AM
Feb-05-24 07:30AM
Jan-31-24 08:42AM
Jan-05-24 07:00AM
Nov-23-23 08:30AM
Nov-03-23 09:00AM
Nov-01-23 07:30AM
Oct-20-23 03:00PM
07:30AM
Oct-06-23 09:00AM
12:00PM Loading…
Oct-04-23 12:00PM
Sep-21-23 08:30AM
Sep-19-23 09:00AM
Sep-08-23 08:00PM
Sep-07-23 07:30AM
Sep-04-23 12:00PM
Sep-01-23 09:20PM
Aug-31-23 12:44AM
Aug-24-23 12:25AM
Aug-23-23 02:06AM
Aug-22-23 07:30AM
Aug-13-23 10:24AM
Aug-10-23 07:30AM
Aug-08-23 01:04AM
Jul-28-23 08:00PM
01:22AM Loading…
Jul-25-23 01:22AM
Jul-21-23 04:15PM
12:57AM
Jul-20-23 01:05AM
Jul-19-23 08:00AM
12:37AM
Jul-18-23 08:37AM
Jul-12-23 01:00AM
Jul-07-23 09:00PM
Jul-06-23 08:17AM
12:51AM
Jul-05-23 08:35AM
Jun-29-23 09:03PM
Jun-28-23 08:35AM
Jun-02-23 10:15AM
Jun-01-23 11:59AM
May-31-23 12:59AM
May-30-23 07:30AM
May-26-23 06:00PM
May-25-23 05:00PM
May-23-23 07:30AM
May-09-23 07:15AM
May-08-23 07:30AM
May-02-23 03:30PM
Apr-19-23 09:11AM
Apr-18-23 09:11AM
Apr-03-23 06:12AM
Mar-23-23 07:30AM
Mar-13-23 07:30AM
Mar-08-23 07:30AM
Feb-27-23 08:30AM
Feb-23-23 07:00AM
Jan-05-23 07:00AM
Jan-04-23 07:00AM
Dec-15-22 07:00AM
Dec-14-22 07:00AM
Dec-02-22 08:15AM
Oct-24-22 09:45AM
Oct-07-22 07:45AM
Sep-08-22 08:15AM
Aug-16-22 07:00AM
Aug-15-22 07:00AM
Jul-13-22 07:00AM
Jun-02-22 07:00AM
May-19-22 08:15AM
May-17-22 08:23AM
May-09-22 08:15AM
May-05-22 08:30AM
Apr-18-22 08:15AM
Mar-31-22 07:05AM
Mar-23-22 08:00AM
Mar-14-22 04:48AM
Mar-02-22 08:00AM
Feb-15-22 09:00AM
Feb-09-22 08:15AM
Jan-31-22 12:04PM
Jan-27-22 11:23AM
Jan-24-22 07:09AM
Jan-10-22 09:17AM
08:34AM
Jan-06-22 08:05AM
Jan-05-22 08:00AM
Jan-04-22 12:27PM
08:00AM
Jan-03-22 02:24PM
12:25PM
09:21AM
08:00AM
06:53AM
06:17AM
Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company's lead product candidate is REQORSA immunogene therapy drug for non-small cell lung cancer. Its other technologies include GPX-002 gene therapy for diabetes, and ONCOPREX nanoparticle delivery system. Genprex was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
VACZY CATHERINE MEVP GC Chief Strategy OfficerApr 21 '23Buy1.0720,00021,478265,000Apr 24 09:00 AM
Varner John RodneyChairman, President and CEOApr 21 '23Buy1.0519,00020,04520,800Apr 24 09:03 AM